Fully-Invested? Why? Thoughts on Microsoft and Eli Lilly, and Celgene
publication date: Jan 3, 2019
Our methodology is really easy to understand once you get to know the things we’re looking at. There’s also some subjectivity in how we implement our thoughts in the simulated newsletter portfolios, and please stop calling what we do advice. We’re a financial publisher. While we’re at it, let’s talk a bit about Microsoft, Eli Lilly, and Celgene through the lens of our methodology.
This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!